You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Broad Spectrum Antiviral for Ebola and Marburg viral Infections
SBC: Omm Scientific, Inc Topic: NIAIDDESCRIPTION provided by applicant The long term goal of this project is to gain FDA approval for commercialization of a broad spectrum small molecule antiviral agent that is effective in treating Ebola virus EBOV and Marburg virus MARV These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines The developed drug will inhibit a conserved hum ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Using game mechanics to improve outcomes among stem cell transplant survivors
SBC: Radiant Creative Group, LLC Topic: NCIDESCRIPTION provided by applicant Adolescent and young adult AYA hematopoietic stem cell transplantation HSCT patients face a variety of well documented physical and emotional challenges In addition to undergoing a life threatening procedure that involves an intense treatment regimen and lengthy hospital stay these patients face a protracted month recovery period marked by numerous phy ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
APPSPIRE: expanding the reach of an innovative tobacco control program for youth
SBC: Radiant Creative Group, LLC Topic: NIDADESCRIPTIONprovided by applicantMobile phone technology offers a variety of opportunities for innovative approaches to health communication and interventionThese opportunities have been amplified by the emergence of next generation smartphone devices that are capable of rich multimedia and sophisticated interactivitySmartphone based programs can be integrated seamlessly into a userandapos s daily ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A novel racial disparity marker for risk prediction in triple negative breast cancer patients
SBC: NOVAZOI THERANOSTICS Topic: NIMHDDESCRIPTION provided by applicant Breast cancers in African American AA women are characterized by earlier onset higher aggressiveness more extensive metastases and increased mortality rates compared to those in European American EA women This breast cancer related health disparity is partly due to the fact that AA women are more likely than EA women to develop a particularly aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Ovarian cancer using novel nanoparticle formulations
SBC: KIROMIC BIOPHARMA INC Topic: 102DESCRIPTION provided by applicant Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US It has been observed that the cancer relapses within relatively short periods of time even after the surgery and chemotherapy Therefore immunotherapeutic strategies may serve as an alternative to control the recurrence or progression of ovarian cancer Oral vaccines ar ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: NIAMSDESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
SBC: Pharmareview Corporation Topic: NINDSDESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no available FDA approved therapies for ICH it is of enormous importance to establish effective treatment for this medical condition Following ICH the deposited blood is damaging initially via compression ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Blood-based diagnostics for Alzheimer's Disease
SBC: Amprion, Inc. Topic: NIADESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Triple Re-uptake Inhibitor, SKL 10406, as a New Treatment for Alcohol Dependence
SBC: Medication Discovery Texas, Inc Topic: NIAAADESCRIPTION provided by applicant Three medications are approved by the FDA as treatments for alcohol dependence disulfiram acamprosate and naltrexone but these are seldom prescribed due to poor efficacy or side effects Another topiramate is effective for reducing alcohol use but it causes a range of side effects that limit its tolerability Another clas of potentially effective treatment ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health